HOPKINTON, Mass., April 16 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc., (Nasdaq: BLSI - News), a biopharmaceutical company focused on the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders, announced today the appointment of Frank Bobe, Ph.D. as Executive Vice President and Chief Business Officer. Dr. Bobe will be responsible for managing and expanding the Company’s commercial and corporate development activities.
“Frank joins Boston Life Sciences during a very exciting period as we transition our company’s focus to the development of therapeutic solutions for nerve repair,” said Chief Executive Officer Peter Savas. “Frank’s proven track record in cultivating and structuring research and development partnerships and identifying new business opportunities, combined with his broad commercial experience, will add to the depth and breadth of our executive team as we seek to expand and mature our development pipeline.”
Dr. Bobe has over 20 years of biotechnology and pharmaceutical industry experience. He joins Boston Life Sciences from BioAxone Therapeutic, Inc. of Canada, where he served as President and Chief Executive Officer since March 2005. In addition to initiating BioAxone’s clinical trial of Cethrin in acute spinal cord injury, Dr. Bobe was responsible for guiding BioAxone’s corporate strategy, developing its operating plan, and advancing its technical development platforms. Dr. Bobe played a key role in BioAxone’s licensing of Cethrin and related intellectual property and technology to Boston Life Sciences for nerve repair therapies following debilitating injuries to the spinal cord.
Prior to joining BioAxone, Dr. Bobe was Chief Executive Officer and Country Head of the South Korean affiliate of Novartis AG, where he successfully launched several brands, implemented alliances with local and global partners and built a new management team. Prior to joining Novartis Korea, Dr. Bobe held operational management and global corporate leadership positions at Novartis AG, with increasing responsibilities in preclinical research, sales and marketing and general management. Dr. Bobe holds a Ph.D. in Bio-organic Chemistry from the University of California at Davis and completed a postdoctoral research fellowship in biochemistry in the laboratory of Nobel Laureate Prof. Bruce Merrifield, Rockefeller University, New York. Dr. Bobe also holds an MBA from INSEAD in Fontainebleau, France.
About Boston Life Sciences
Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. ALTROPANE®, a molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson’s Disease (PD). The Company’s research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson’s disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. BLSI’s current research collaborations include Harvard Medical School and Children’s Hospital Boston.
Safe Harbor
The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences’ future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company’s licensing arrangement with BioAxone, including the development and commercialization of Cethrin, the prospects of the Company’s CNS therapeutics program, the Company’s strategies to develop and commercialize axon regeneration technologies and the breadth of the Company’s technologies and intellectual property portfolio. Forward- looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company’s Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.
Contact: Sharon Correia Boston Life Sciences, Inc. +1-508-497-2360 ext. 224 scorreia@bostonlifesciences.com
Source: Boston Life Sciences, Inc.
